Dermatology

Given the distrust some patients with conditions such as alopecia areata and psoriasis have regarding JAK inhibitors, this analysis highlights several approaches to such concerns.

This analysis was conducted to evaluate whether genetic risk of hidradenitis suppurativa was linked to greater risk of future cardiometabolic disease.

The Accure Laser System is indicated for long term treatment of patients known to have mild to severe inflammatory acne vulgaris.

This online diagnostic tool’s implementation among study participants led to increased confidence in making diagnoses of chronic plaque psoriasis.

This analysis indicates that patients with a history of a first melanoma are at risk for subsequent development of melanoma regardless of their race or their ethnicity.

These data highlight barriers to pediatric treatments for eczema, providing potential strategies for caregivers and patients for adherence improvement.

New research reveals amyl nitrite (poppers) use is linked to dermatitis, with perianal and perioral regions most affected.

These new data provide additional evidence for a range of benzene concentrations detected by in over-the-counter drug products with BPO maintained at room temperature.

The decision by the FDA follows an announcement by Biofrontera that there were no safety issues found following the submission of the medication’s supplemental New Drug Application.

In this Month in Review, we highlighted some of the most notable stories covered in the dermatology space during September 2024.

New data reports a notably heightened risk of atopic dermatitis in patients with prurigo nodulais compared with a control cohort.

A new post-hoc analysis has also revealed improvements in quality of life in patients’ caregivers.

A study shows secukinumab clears skin lesions faster than ustekinumab in generalized pustular psoriasis, with improved responses observed by week 2.

A review of 5 highly anticipated FDA decisions expected by year-end, including acoramidis for ATTR-CM, olezarsen for FCS, sotagliflozin for T1D and CKD, and more.

Study findings highlight the individual and combined impact of smoking tobacco and drinking alcohol on achieving PASI75 after 8 weeks of treatment.

An EADV 2024 study suggests dupilumab use during pregnancy is generally safe and may lower risks of preterm labor, gestational hypertension, and diabetes.

Crisugabalin at 40 mg/d or 80 mg/d significantly reduced daily pain in adults with postherpetic neuralgia, a phase 3 study found.

Further research is needed to understand the mechanism behind the link as antibiotic exposure is often necessary in care.

A small percentage of participants with psoriasis reported adequate adherence, with nearly half showing low adherence to phototherapy treatment.

Contrary to previous research, findings suggest no significant difference in infertility between patients with HS, other dermatological diseases, and healthy controls.

These data were presented at EADV 2024 by UCB, with presenters highlighting positive long-term efficacy findings for bimekizumab among patients with plaque psoriasis.

The phase 3b/4 findings from PSORIATYK SCALP suggest that oral deucravacitinib led to significant improvements for patients with scalp psoriasis.

This segment of Marghoob’s interview featured a discussion of pigmented lesion identification and use of technology such as AI.

These new data demonstrate that bimekizumab was both effective and well-tolerated over the course of 2 years for patients with hidradenitis suppurativa.

Ruxolitinib cream offers an effective nonsteroidal treatment for mild to moderate atopic dermatitis, with proven efficacy and safety for sensitive skin areas.

In this interview, Marghoob highlights some of the biggest diagnostic challenges faced by dermatologists and other providers when it comes to pigmented lesions.

New data presented by Sun Pharma at EADV 2024 highlight the impact of deuruxolitinib 8 mg treatment of adults with severe alopecia areata.

In this interview at EADV, Thaçi was asked to highlight his team’s recent data from the ARCADIA trial program on nemolizumab for patients with eczema.

The 9-month interim results of the TRACE study were presented at EADV 2024, highlighting tralokinumab’s efficacy in a subset of patients with eczema impacting the head and neck areas.

These new data were announced by Celldex Therapeutics regarding the sustained and deepening efficacy of barzolvolimab treatment of chronic spontaneous urticaria.